Tag: mainstream media

Politico’s Defense News, Brought to You by Northrop Grumman

Since its inception 14 years ago, Politico has risen to become an internet news giant. Now employing over 700 people and reaching 50 million people per month, the website and newspaper has become one of the most trusted sources of information on political issues in the United States. Key to this is its range of influential newsletters, which reach millions every day.

And yet the organization has entered into a number of very troubling partnerships that could potentially undermine the credibility and independence of its reporting. Both its defense and space newsletters, which keep readers informed and up to date on those topics, come sponsored by giant military and aerospace contractor Northrop Grumman.

To its credit, Politico is upfront about their partnership, with those sections bearing an advertisement label stating “presented by Northrop Grumman.” The question is whether readers can truly trust the outlet to accurately report and scrutinize those areas that are so critical to its chief sponsor. Does taking Northrop Grumman’s money make Politico less likely to call out the Pentagon’s enormous and bloated military budget, war crimes committed overseas, or the gross wastage of public funds?

Keep reading

Newsweek ‘Fact Check’ Claims India Vaccine Ban “Mostly False” While Admitting De Facto Ban

Newsweek published a “fact check” which labeled claims that India had banned the Pfizer-BioNTech vaccine as “mostly false” despite admitting in the article that India has in fact temporarily banned the vaccine.

Last week, discussion around the issue intensified after it was revealed that Indian health authorities had refused to give permission for the vaccine to be distributed.

“On February 3, 2021, India’s Subject Expert Committee (SEC), a panel that advises the nation’s Central Drugs Standard Control Organisation (CDSCO), a national regulatory body focused on pharmaceuticals and devices, ruled that the Pfizer-BioNTech vaccine should not be recommended for an EUA in the country “at this stage,” reports Newsweek.

The report quotes India’s Subject Expert Committee (SEC), which ruled, “The committee noted that incidents of palsy, anaphylaxis and other SAE’s have been reported during post marketing and the causality of the events with the vaccine is being investigated. Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population.”

In response, after the meeting with the regulator, Pfizer Inc. withdrew its application for the vaccine’s use in India.

Keep reading